Received Feb 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | UNK | NA4452 | IM / LA |
| FLU3 | INFLUENZA (SEASONAL) (FLUCELVAX) | SEQIRUS, INC. | N/A | 39R9B | IM / LA |
Severe fatigue, mild tachychardia, soreness at injection site, swollen and painful lymph node(s) near injection site (armpit, collarbone). Experienced these same symptoms in September 2024 after receiving the season?s flu and COVID-19 vaccinations. Symptoms resolved within 1 week, and the same timeline is expected this time around as well. Submitting this form for data reporting information only.
Vyvanse: 40 mg
The same vaccinations as indicated in this report, September 2024